Boryung Corporation (KRX:003850)
South Korea
· Delayed Price · Currency is KRW 9,030.00
-10.00 (-0.11%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| Specialty Care | 304.02B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology (Anticancer) | 241.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hypertension/Dyslipidemia | 177.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Over the Counter Drug | 86.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trust | 70.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Renal | 66.87B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes | 52.24B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Central Nervous System | 19.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -635.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufactured Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufactured Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| South Korea | 1,017.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | 18.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|